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Abstract Familial adenomatous polyposis (FAP) pro-
vides a model for sporadic colorectal cancer development.
Cyclooxygenase (COX) inhibition may ameliorate polyp
development, but rofecoxib was withdrawn due to cardio-
vascular side effects. Although this selective COX-2
inhibitor, like diet, may alter the fatty acid and eicosanoid
pattern, data on the potential alteration in tissues after use,
are scarce. The aims were to study if rofecoxib might
inﬂuence the fatty acid distribution in serum phospholipids
and duodenal lesions, mRNA for COX-1 and COX-2 in
leucocytes and duodenal lesions, and ﬁnally plasma levels
of PGE2 in a randomized, double-blind, placebo controlled
study (n = 38). Signiﬁcant reductions were found for
essential fatty acid index both in serum phospholipids
(P = 0.01, 95% CI =- 0.9; -0.1), and in duodenal
lesions (P = 0.04, 95 CI % =- 0.9; -0.1) after treatment.
No treatment effects were found on the COX mRNA
expression, or in the plasma PGE2 levels. Dietary AA/EPA
ratio was inversely associated with all the indicators of
EFA status (all P\0.01). These ﬁndings suggest that the
effects of COX chemoprevention should be further inves-
tigated in FAP and that dietary needs should be included in
the treatment of FAP.
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Introduction
Rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, was
withdrawn because of increased risk of adverse cardio-
vascular events and metabolic complications [1–6]. The
link between COX-2, fatty acids and risk of several dis-
eases has been widely accepted [7, 8]. Deregulation of the
COX-2/PGE2 pathway appears to affect tumorigenesis via
a number of distinct mechanisms: Promoting tumour
maintenance and progression, encouraging metastatic
spread, and perhaps even participating in tumour initiation
[9]. COX-1 and -2 are the rate limiting enzymes in the
synthesis of prostaglandins and thromboxanes [10]. Ara-
chidonic acid (AA) is the main substrate for these enzymes,
leading to the synthesis of prostaglandins which have
growth promoting effects. Substituting AA with omega-3
fatty acids has been shown to lead to the production of less
potent prostaglandins [11]. Since COX-2 is a fatty acid
metabolising enzyme, the effects of COX-2 inhibition on
fatty acid composition of different tissues is of interest.
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DOI 10.1007/s10689-010-9365-2Although refecoxib has been used as chemoprevention
against cancer, the underlying mechanisms relevant to fatty
acids and colorectal cancer (CRC) have, to our knowledge,
not been elucidated.
Familial adenomatous polyposis (FAP) accounts for 1%
of CRCs [12], and provides a model for sporadic cancers.
CRC arising in FAP patients can be largely prevented by
polyp surveillance and prophylactic colectomy [13].
However, these patients remain at cancer risk at other sites,
particularly duodenal cancers [14]. COX-2 inhibition is
effective against colorectal polyposis in FAP [15–19].
Moreover, COX-2 expression in FAP patients was higher
in the duodenum compared to the colorectal mucosa in a
previous FAP study [20], offering hope for efﬁcacy even in
duodenal adenoma growth.
Biological mechanisms underlying reported associations
between diet and tissues of CRC are poorly understood
[21]. However, fatty acid metabolic status is an important
substrate for nutrition and also for potentially COX2
inhibitor mediated carcinogenesis. Colectomized FAP
patients have been shown to have a deviant fatty acid
proﬁle with high levels of AA and docosahexaenoic acid
(DHA) and low levels of linoleic acid (LA) and a-linolenic
acid (ALA) in serum phospholipids [22], which is in
accordance with studies in patients with other types of
cancers [23, 24]. One may suspect that increased demand
for essential fatty acids (EFAs) for tissue repair and
membrane formation would lead to EFA deﬁciency,
abnormal precursors of eicosanoids, and suboptimal cell
function [25–27]. If alterations occur in the development of
carcinogenesis, this may affect the biological functions of
EFAs and their derivates. Chronic EFA deﬁciency may
constitute a pro-tumorigenic condition when co-existing
with chronically hyperproliferative states [28]. Very little,
however, is known about fatty acid metabolism in FAP,
although chemoprevention affecting the fatty acid derivates
and the COX enzymes is often administered to this par-
ticular group of patients. Since a regular FAP treatment is
COX-2 inhibition, which, like diet, may alter the fatty acid
and eicosanoid pattern, the aims of this study were to
investigate how rofecoxib inﬂuence the fatty acid distri-
bution in serum and duodenal lesions, and mRNA for
COX-1 and COX-2 in leucocytes and duodenal lesions, in
addition to plasma levels of PGE2.
Materials and methods
Patients were recruited from a Norwegian FAP registry. All
of them had been colectomized and duodenal lesions had
been veriﬁed by endoscopy and histology [29]. Biopsies
were taken partly from macroscopically normal mucosa,
partly from representative visible adenoma. Rikshospitalet
University Hospital is a highly specialized university hos-
pital with national responsibilities in the area of compli-
cated treatments, such as follow-ups on the Norwegian
FAP patients. Inclusion criteria were veriﬁed FAP, colec-
tomy, 18–70 years of age and documented duodenal
lesions graded as Spigelman I, II or III and the largest
adenoma\10 mm. Exclusion criteria were indications for
surgical treatment, suspected or documented intestinal
obstruction or stenosis, patients unwilling or unable to
adhere to protocol, known cardiac failure requiring medical
treatment, and pregnancy. Consecutive patients were
included in a randomized double-blind placebo-controlled
intervention study with Rofecoxib, 25 mg 9 1 daily or
placebo for the duration of 1 year. Of the 47 patients ini-
tially considered for participation, 5 patients did not meet
the inclusion criteria and 4 patients refused to participate.
Thus, data are presented for 38 FAP patients (50% men).
Eleven patients had been operated with conventional and 2
with a continent ileostomy, 20 patients with ileal-pouch-
anal anastomosis (IPAA), 3 patients with ileoanal anasto-
mosis (IAA) and 2 patients with ileorectal anastomosis
(IRA). All patients were on a free diet. The main aim was
to compare the effect of Rofecoxib treatment on duodenal
lesions (data in preparation). Patients are previously
described in detail [30, 31]. The study was interrupted
because Rofecoxib was withdrawn from the market in 2004
due to severe cardiovascular side effects [32]. Eighteen
patients received the intervention for 12 months (44%
placebo). Of 26 patients following the scheduled treatment
for at least 8 months, 50% received placebo. Of 8 patients
following the treatment for less than 8 months, 50%
received placebo. Mean placebo and Refecoxib duration
was 9.8 ± 2.9 months and 8.8 ± 3.5 months, with mean
compliance to the treatment of 85 and 90%, respectively.
Dietary intake
The habitual dietary intake has been described previously
[33]. Data was gathered using a retrospective interview
according to a validated food frequency questionnaire,
focusing on the 1 year prior to inclusion in the study.
Fatty acids analyses in serum phospholipids and in total
lipids of duodenal lesions
Total fatty acids in duodenal lesions (10–40 mg) were
extracted with chloroform/methanol, transmethylated and
determined by gas chromatography (vide supra). Fasting
serum lipids were extracted using n-butanol and phospho-
lipids isolated from the lipid extracts using Varian Bond
Elut NH2, LCR columns (Varian, Walnut Creek, CA).
Composition of fatty acids in serum phospholipids in these
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123FAP patients at baseline as compared to a healthy reference
material (n = 160), has been published previously [34].
The results of the measurements are presented as weight
pecentage of total fatty acid analysed. The fatty acids were
14:0 (myristic acid), 16:0 (palmitic acid), 16:1n-7 (palmit-
oleic acid), 18:0 (stearic acid), 18:1n-9 (oleic acid), 18:2n-6
(linoleic acid, LA), 18:3n-3 (a-linolenic acid, ALA), 20:1n-
11 (eicosaenoic acid), 20:2n-6 (eicosadienoic acid), 20:4n-6
(arachidonic acid, AA), 20:5n-3 (eicosapentaenoic acid,
EPA) and 22:6n-3 (docosahexaenoic acid, DHA). Dihomo-
c-linolenic acid (20:3n-6) and eruic acid (22:1n-9) were
present in very small amounts, and these fatty acids are only
included in sums. An estimate of delta- 9-desaturase
(steaoryl-CoA desaturase, SCD) activity was calculated as
ratios of 16:1n-7/16:0 and 18:1n-9/18:0. A measure of EFA
status is the ratio of (sum omega-3 and sum omega 6 fatty
acids) to (sum omega-7 and omega-9 fatty acids), since
deﬁciency in ALA and LA would depress the entire omega-
3 and omega-6 series
11, respectively.
RNA isolation and cDNA synthesis
Leucocytes were isolated from fasting blood samples,
collected in EDTA tubes. The EDTA tubes were centri-
fuged and plasma removed. Red blood cells were lysed by
red blood cell lysis buffer, and leucocytes isolated by
centrifugation. Cell pellets containing leucocytes were
immediately placed on dry ice and stored at -80C. RNA
was isolated by the Trizol/RNeasy hybrid protocol: Chilled
Trizol reagent (Invitrogen,TM Life Technologies) was
added to the frozen cells and immediately mixed by vor-
texing. The homogenized samples were incubated at room
temperature for 5 min before the addition of 0.2 ml chlo-
roform per ml Trizol reagent. Each tube was vortexed for
15 s, incubated at room temperature for another 5 min and
centrifuged at 12,0009g (4C) for 10 min. The upper
aqueous phase was transferred to a new tube and an equal
volume of 70% ethanol (4C) was added during continuous
mixing. Each sample was then transferred to an RNeasy
mini column (Qiagen), and further RNA isolation was done
by following the manufacturer’s instructions. All samples
were treated with Rnase-free Dnase (Qiagen) to prevent
ampliﬁcation of genomic DNA. RNA quality was checked
by Capillary electrophoresis (RNA 600 Nano LabChip,
Agilent) on an Agilent Bioanalyser 2100 system. The total
RNA yield was measured on a Nanodrop ND-1000 Spec-
trophotometer (NanoDrop Technologies Wilmington,
Delaware, USA). For cDNA synthesis, RNA from each
sample was reverse-transcribed by Super Script (Invitro-
gen) according to the manufacturer’s protocol, using oligo
dT as primers.
RNA isolation from duodenal lesions
Lesions were taken and stored in RNAlater solution pre-
vious to freezing at -80C. Each biopsy was put into a
tube containing 600 ll Trizol and immediately mixed on a
MixerMill (Retsch GmbH, Germany). RNA was isolated
from the samples as described above.
Real time polymerase chain reaction
Gene expression analyses were carried out on a 7900HT
real time PCR machine from Applied Biosystems. Based
on the results from running a housekeeping gene test
(‘‘TaqMan Human Endogenous Control Plate’’, Applied
Biosystems) with RNA from isolated human leucocytes
(data not shown), Glucuronidase (GUS) and Tata binding
protein (TBP) were chosen as housekeeping genes. The
primers and probes were initially designed as three assays
per gene, and validated for efﬁciency and speciﬁcity. The
best of the three was then chosen. The primers and probes
for the COX-1 assay were: forward primer: 50-CTTCCAG
GAGCTCGTAGGA-30, probe: 50-AGAAGGAGATGGCA
GCAGAGTTGGAG-30, and reverse primer: 50-ACGCA
TCAATGTCTCCATACAAT-30. COX-2 forward primer:
50-TGGAACATGGAATTACCCAGT-30, probe: 50-TGT
TGAATCATTCACCAGGCAAATTGCT-30 and reverse
primer: 50-TCCTACCACCAGCAACCCT-30. GUS for-
ward primer: 50-GAAAATATGTGGTTGGAGAGCTC
ATT-30, probe: 50-CCAGCACTCTCGTCGGTGACTGTT
CA-30 and reverse primer: 50-CCGAGTGAAGATCCCC
TTTTTA-30. TBP forward primer: 50-CTGGAAAAGTTG
TATTAACAGGTGC-30, probe: 50-AGCAGAAATTTATG
AAGCATTTGAAAACATCTACCCTATT-30 and reverse
primer: 50-CATTACGTCGTCTTCCTGAATC-30.
TaqMan Universal PCR Master Mix (Applied Biosys-
tems) was added as reaction mix. The reaction conditions
were initiated by a step of 2 min. at 50C and 10 min. at
95C,followedby40cyclesofdenaturationat95Cfor15 s.
and annealing at 60C for 1 min. Standards and samples
were analysed in triplicates for all assays. A combination of
cDNAfromseveralsampleswasmadeanddilutedinorderto
make a dilution curve that was included on each plate. The
average of the three values for each gene was divided by the
average of the corresponding GUS and TBP values, gener-
ating a normalized value of the gene expression which is a
unitlessvalueusedtocomparetherelativeamountofmRNA
for each gene in the different samples. For comparison, we
also analysed leucocytes from 59 Norwegian blood donors
(mean age: 41 ± 12 years, 49% men). Normal duodenal
tissue (n = 11) was provided from clinicians in the hospital
(anonymous, but healthy samples).
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123PGE2 in plasma
Plasma samples were analysed for PGE2 by ELISA (R&D,
London, UK), according to the manufacturer’s instructions.
Ethics approval
The study was performed in accordance with the Helsinki
Declaration. Patients were informed by a physician, and
thorough written information was provided to all patients.
The protocol was explained to the subjects, who gave their
consent before inclusion. No honorarium was offered. The
patients were informed speciﬁcally of the option to with-
draw at any stage of the study with no requirement to
provide an explanation for withdrawal. The study protocol
(RH01/01) was approved by the Norwegian health
authorities and the Regional Committee of Medical Ethics
20/06/2002 (reference: S-02127). At cessation of the study,
all patients were informed personally about the reasons for
drug withdrawal and any consequences relevant to the
individual patient. Retrospective registration was done
02/13/09 at ClinicalTrials.gov.
Statistical analysis
This group of patients is very rare, and the present sample
size is close to the maximum possible number of eligible
Norwegian FAP patients. Results are expressed as mean
values ± standard deviation (SD), or as stated. The effect
of each treatment was analysed separately in each group by
Student’s paired t tests. Differences in mean values
between groups are tested by Independent-Samples T tests.
Relations between variables were investigated using Pear-
son’s correlation coefﬁcients (r). We included the results
from all the included patients in the tables. However, since
the trial was interrupted, we have also provided footnotes
that include analysis excluding the cases that followed the
treatment for less than 8 months. Statistical signiﬁcance
was set to P B 0.05. All statistical analyses were per-
formed with the SPSS 12.0 for Windows.
Results
Relative composition of fatty acids in serum
phospholipids
The composition of fatty acids in serum phospholipids at
baseline and after the intervention, expressed as weight
percentage of total fatty acids analysed, are presented in
Table 1.
In both groups, the relative amounts of several fatty
acids increased in serum phospholipids, whereas the
relative amount of DHA (P\0.03) decreased in the
intervention period. However, a signiﬁcant treatment effect
was observed only for myristic acid (P = 0.02, 95%
CI =- 0.4; -0.04) and eicosaenoic acid (P = 0.01, 95%
CI = 0.02; 0.1). After exclusion of the patients who
received treatment for less than 8 months, signiﬁcant
treatment effects were found also for the different estimates
of essential fatty acid status: EFA index (P = 0.01, 95%
CI =- 0.9; -0.1), PUFA/(SAT ? MUFA) (P = 0.02,
95% CI =- 0.3; -0.1), and sum omega-7 and omega-9
fatty acids (P = 0.01, 95% CI = 1.3; 8.1).
Relative composition of fatty acids in duodenal lesions
Signiﬁcant treatment effects were observed in duodenal
lesions for LA, PUFA, omega-6 fatty acids, EFA index,
ratio PUFA/(SAT ? MUFA), oleic acid, MUFA, omega-9
fatty acids, and sum omega-7 ? omega-9 fatty acids (all
P\0.05) (Table 2). Exclusion of the cases that had
received treatment for less than 8 months did not change
these results.
Gene expression in blood and duodenal lesions
No signiﬁcant treatment effects were found on mRNA
expression levels of COX-1 and COX-2, nor plasma levels
of PGE2. In the Rofecoxib group separately, however, the
duodenal expression levels of COX-1 was increased
(P = 0.03, 95% CI =- 0.20; -0.01), but this reached
statistical signiﬁcance for only one of the two housekeep-
ing genes (Table 3).
The mRNA COX-1 and COX-2 expression in leucocytes
from FAP patients was lower than in healthy individuals,
but only signiﬁcantly so when using GUS as the house-
keeping gene (P\0.001, 95% CI =- 0.5; -0.2, and
P\0.01, 95% CI =- 1.6; -0.2, respectively). The COX-
1 expression in duodenal lesions from FAP patients was
lower than in normal lesions, regardless of choice of
housekeeping gene (both P\0.01). The levels of COX-2
expression in duodenal lesions and plasma PGE2 did not
vary between FAP patients and healthy subjects (data not
shown).
Relationship to dietary intake of fatty acids
The dietary AA/EPA ratio was inversely associated with
duodenal EFA index (r =- 0.4, P = 0.01) and ratio
PUFA/(SAT ? MUFA) in both serum phospholipids and
duodenal lesions (both r =- 0.4, P\0.01). In serum
phospholipids, habitual use of omega-3 fatty acid supple-
ments was associated with higher levels of EPA (P = 0.01),
DHA (P = 0.02), PUFA (P = 0.006), omega-3 fatty acids
(P = 0.007), ratio omega-3/omega-6 (P = 0.01) and ratio
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acid supplements was associated with lower duodenal levels
of oleic acid (P = 0.04) and MUFA (P = 0.03), and higher
duodenal levels of EPA (P = 0.002), DHA (P = 0.01),
ratio EPA/DHA (P = 0.04) and EFA index (P = 0.046)
(data not shown).
We wanted to see if the habitual intake of omega-3 and
omega-6 fatty acids were related to the treatment effects.
Results were signiﬁcant for the habitual intake of omega-6
fatty acids in particular as compared to the changes of fatty
acid composition in duodenal lesions (Table 4). No sig-
niﬁcant coefﬁcients of correlation were found as compared
to the changes in fatty acid composition in serum phos-
pholipids, expression of COX-1 and COX-2, and plasma
levels of PGE2 (data not shown).
Discussion
Rofecoxib has no likely therapeutic future because of
concerns relative to cardiovascular toxicity. However,
investigation of the effects of this selective COX-2 inhib-
itor on nutrition-related parameters is still relevant in order
to improve treatment and care of FAP.
In the present study, comparable treatment effects were
observed on the fatty acid composition in serum phospho-
lipids and duodenal lesions, presumably and most impor-
tantly the non-beneﬁcial effects involving EFAs. Treatment
effects were observed neither on mRNA expression levels
of COX-1 and COX-2 in duodenal lesions and leucocytes,
nor on the levels of plasma PGE2. Dietary intake of fatty
acids was reﬂected in the composition of fatty acids in both
serum phospholipids and duodenal lesions. Furthermore,
intake of omega-3 fatty acids was beneﬁcially related to
increased levels of estimates of EFA status.
Several of the present estimated changes suggest insuf-
ﬁcient EFA status [35, 36]. Generally, in EFA deﬁciency,
both palmitoleic acid and oleic acid are elongated and
desaturated when delta-6 desaturase is stimulated, and this
process is considered as an ineffective attempt to replace
EFAs with the long chain metabolites, primarily 5, 8, 11
eicosatrienoic acid (mead acid). EFA deﬁciently also
induces an increased activity of delta-9 desaturase, which
might account for the abnormal increase in palmitoleic acid
in serum phospholipids in both the placebo and Rofecoxib
group separately. In many tumour cells, the metabolism of
EFA is clearly abnormal, since there is a partial or com-
plete loss of delta-6 desaturase. A dietary deﬁciency of
Table 1 Fatty acid composition of serum phospholipids (weight %) from patients with familial adenomatous polyposis before and after
treatment with Rofecoxib
Placebo group Rofecoxib group 95% CI
b
At baseline
n = 17
After intervention
n = 15
P value
a At baseline
n = 18
After intervention
n = 15
P value
a P value
b,c Lower Upper
Fatty acids (weight %) in serum phospholipids
Myristic acid 0.1 ± 0.01 0.8 ± 0.2 \0.01 0.01 ± 0.01 0.6 ± 0.2 \0.01 0.02 -0.4 -0.04
Palmitoleic acid 0.3 ± 0.4 0.6 ± 0.3 \0.001 0.4 ± 0.3 0.6 ± 0.3 0.007 0.9 -0.2 0.2
ALA 0.1 ± 0.1 0.2 ± 0.2 \0.01 0.01 ± 0.04 0.2 ± 0.2 \0.01 0.4 -0.1 0.1
Eicosaenoic acid 0.1 ± 0.1 0.01 ± 0.01 0.9 0.01 ± 0.01 0.1 ± 0.1 \0.01 0.01 0.02 0.1
Eicosadienoic acid 0.2 ± 0.5 0.3 ± 0.3 0.3 0.1 ± 0.2 0.3 ± 0.2 \0.001 0.7 -0.3 0.4
EPA 1.7 ± 1.0 1.9 ± 0.9 0.6 1.5 ± 0.8 1.9 ± 0.8 0.03 0.6 -0.6 0.9
DHA 11.2 ± 2.7 9.9 ± 2.2 0.02 11.0 ± 3.2 9.9 ± 1.9 0.03 0.8 -1.4 1.9
Palmitoleic/
palmitic acid
0.01 ± 0.1 0.02 ± 0.1 \0.001 0.01 ± 0.1 0.1 ± 0.1 0.004 0.9 -0.1 0.1
EPA/DHA 0.2 ± 0.1 0.2 ± 0.1 0.2 0.1 ± 0.1 0.2 ± 0.1 0.006 0.8 -0.1 0.1
Results are presented as mean ± standard deviation
a P value: between baseline and intervention
b P value: treatment effect: difference between end value and start value
c The results for palmitic acid, stearic acid, oleic acid, LA, AA, SAT, MUFA, PUFA, sum omega-3 fatty acids, sum omega-6 fatty, omega-3/
omega-6 fatty acids acids, sum omega-9 fatty acids, LA/AA, EFA index
d, PUFA/(SAT ? MUFA) and sum omega-7 and omega-9 fatty acids
were not signiﬁcant (all subjects) (data not shown in Table). After exclusion of the patients that were compliant for less than 8 months (n = 4,
50% placebo), similar treatment effects were found for the same fatty acids: myristic acid (P = 0.02, 95% CI =- 0.4; -0.1) and eicosaenoic
acid (P = 0.02, 95% CI = 0.01; 0.1), and additionally for EFA index (P = 0.01, 95% CI =- 0.9;-0.1), PUFA/(SAT ? MUFA) (P = 0.02,
95% CI =- 0.3; -0.1), and sum omega-7 and omega-9 fatty acids (P = 0.01, 95% CI = 1.3; 8.1)
d EFA index: (sum omega-3 fatty acids and sum omega 6 fatty acids) / (sum omega-7 and omega-9 fatty acids)
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predispose to the development of cancer [37]. We did not
introduce any conscious dietary intervention that would
have accounted for the signiﬁcant increases in several FAs
post treatment in the placebo group. One may suspect that
increased demand for EFAs for tissue repair and membrane
formation would lead to EFA deﬁciency, abnormal pre-
cursors of eicosanoids, and suboptimal cell function (1–3).
Chronic EFA deﬁciency may constitute a pro-tumorigenic
condition when co-existing with chronically hyperprolif-
erative states, and disease development might also explain
some of the ﬁndings. It may be that serum phospholipids
are poor short term indicators of EFAD status except in
severe EFAD. This may offer an explanation for why
signiﬁcant ﬁndings were predominately found in duodenal
lesions which may reﬂect dietary intake over a longer
period of time.
Presently, the estimated activity of SCD in serum phos-
pholipids was increased in both the placebo and Rofecoxib
group,butnotreatmenteffectwasfound.Thedietarycontent
of palmitoleic acid is low, and most palmitoleic acid in
serum is derived from the desaturation of palmitic acid
catalysed by SCD. The level of the other main product of
SCD desaturation, oleic acid, was increased after treatment
in duodenal lesions. The strong correlation of high levels of
MUFA and neoplastic phenotype suggest that the regulation
of SCD might play a role in cancer development. SCD is the
central lipogenic enzyme catalyzing in vivo reactions in the
synthesis of MUFAs, particularly oleic acid and palmitoleic
acid, which are the major MUFAs of membrane phospho-
lipids, triglycerides, wax esters, and cholesteryl esters.
An increased desaturation estimated as a decreased ratio
of stearic acid/oleic acid [38], was not found in this
investigation.
Treatment lowered the levels of LA and omega-6 fatty
acids in duodenal lesions as compared to placebo. A posi-
tive correlation was found between dietary intake of omega-
6 fatty acids and duodenal amounts of LA at baseline.
Table 2 Fatty acid composition of duodenal lesions (weight %) from patients with familial adenomatous polyposis before and after treatment
with Rofecoxib
Placebo group Rofecoxib group 95% CI
2
At baseline
n = 16
After intervention
n = 12
P value
a At baseline
n = 17
After intervention
n = 13
P value
a P value
b, c Lower Upper
Fatty acids (weight %) in duodenal lesions
Oleic acid 20.2 ± 4.3 20.2 ± 2.8 0.3 18.7 ± 0.9 21.4 ± 3.6 0.04 0.04 0.2 6.7
LA 24.9 ± 3.3 25.3 ± 2.8 0.3 27.3 ± 2.3 25.3 ± 3.7 0.07 0.03 -6.4 -0.3
MUFA 21.2 ± 1.2 21.1 ± 2.8 0.3 19.6 ± 1.4 22.4 ± 3.9 0.04 0.03 0.3 6.9
PUFA 39.4 ± 6.0 40.4 ± 2.6 0.2 42.4 ± 2.0 39.2 ± 5.4 0.04 0.03 -9.7 -0.7
Sum omega-6 fatty
acids
35.2 ± 5.1 36.2 ± 2.3 0.2 38.3 ± 2.2 35.3 ± 5.5 0.07 0.03 -9.1 -0.5
Sum omega-9 fatty
acids
20.3 ± 4.3 20.2 ± 2.7 0.3 18.8 ± 1.4 21.4 ± 3.6 0.04 0.04 0.2 6.7
EPA/DHA 0.3 ± 0.1 0.4 ± 0.1 0.3 0.3 ± 0.01 0.4 ± 0.1 0.03 0.9 -0.1 0.1
EFA index
d 2.0 ± 0.6 2.0 ± 0.4 0.3 2.2 ± 0.3 1.9 ± 0.5 0.04 0.04 -0.9 -0.1
PUFA/
(SAT ? MUFA)
0.7 ± 0.2 0.7 ± 0.1 0.3 0.7 ± 0.1 0.7 ± 0.1 0.04 0.03 -0.2 -0.1
Sum omega-7 ?
omega-9 fatty acids
4.4 ± 3.3 3.6 ± 1.4 0.3 3.2 ± 0.8 4.1 ± 2.2 0.3 0.03 0.3 6.9
Results are presented as mean ± standard deviation
a P value: between baseline and intervention
b P value: treatment effect: difference between end value and start value
c The results for myristic acid, palmitic acid, palmitolic acid, stearic acid, ALA, eicosaenoic acid, eicosadienoic acid, AA, EPA, DHA, SAT, sum
omega-3 fatty acids, omega-3/omega-6 fatty acids, palmitolic acid/palmitic acid, oleic acid/stearic acid and AA/LA, were not signiﬁcant (all
subjects) (data not shown in Table). After exclusion of the patients that were compliant for less than 8 months (n = 3), similar treatment effects
were found for the same fatty acids: oleic acid (P = 0.01, 95% CI = 1.2; 7.8), LA (P = 0.046, 95% CI =- 0.7; -0.1), MUFA (P = 0.009,
95% CI = 1.3; 8.1), PUFA (P = 0.02, 95% CI =- 10.9; -1.3), omega-6 fatty acids (P = 0.03, 95% CI =- 10.2; -0.7), omega-9 fatty acids
(P = 0.01, 95% CI =- 1.2; -7.8), EFA index (P = 0.01, 95% CI = 1.2; 7.8), omega-9 fatty acids (P = 0.01, 95% CI =- 1.2; -7.8), EFA
index (P = 0.01, 95% CI =- 0.9; -0.1), PUFA/(SAT ? MUFA) (P = 0.02, 95% CI =- 0.3; -0.1), and sum omega-7 and omega-9 fatty
acids (P = 0.01, 95% CI = 1.3; 8.1)
d EFA index: sum omega-3 fatty acids ? sum omega-6 fatty acids/sum omega-7 fatty acids ? sum omega-9 fatty acids
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123Dietary intake of omega-6 fatty acids will increase the
formation of AA; hence, more PGE2 is formed [39]. In this
study the dietary ratio of omega-6 fatty acids/omega-3 fatty
acid correlated positively to PGE2 values. Dietary omega-3
fatty acids are regarded as beneﬁcial, as their desaturat-
ed metabolites competitively inhibit the production of
AA-derived eicosanoids such as prostaglandins and
leucotrienes, which are potent mediators, and some of these
mediators are known to be involved in inﬂammation. On the
other hand, lipoxins, which are anti-inﬂammatory, can also
be synthesized from AA[40].
Selective COX-2 inhibitors were developed with the goal
of inhibiting PGE2 synthesis in areas of inﬂammation. PGE2
is known to be a tumour promoter, and isoften found inhigh
Table 3 mRNA expression of COX-1 and COX-2 in leucocytes and duodenal lesions and levels of plasma PGE2 in patients with familial
adenomatous polyposis before and after treatment with Rofecoxib
Placebo group Rofecoxib group P value
b,c 95% CI
2
At baseline After intervention P value
a At baseline
n = 18
After intervention
n = 15
P value
a
n = 15 n = 13
Leucocytes
COX-1 G 0.6 ± 0.3 0.4 ± 0.2 0.45 0.6 ± 0.2 0.7 ± 0.7 0.4 0.3 -0.20 0.61
COX-1 T 2.4 ± 1.2 2.0 ± 0.8 0.63 2.9 ± 1.5 3.4 ± 2.4 0.3 0.3 -0.68 2.20
COX-2 G 1.5 ± 1.9 1.2 ± 0.6 0.69 1.8 ± 1.2 1.6 ± 1.4 0.5 0.9 -1.54 1.40
COX-2 T 4.6 ± 3.3 5.8 ± 3.1 0.19 8.3 ± 5.0 6.7 ± 5.1 0.2 0.08 -7.72 0.65
Duodenal lesions
COX-1 G 1.1 ± 1.2 1.2 ± 0.2 0.19 1.1 ± 0.2 1.2 ± 0.2 0.1 0.8 -0.15 0.20
COX-1 T 0.9 ± 0.2 0.9 ± 0.2 0.62 0.9 ± 0.2 1.01 ± 0.2 0.03 0.2 -0.05 0.20
COX-2 G 1.2 ± 0.2 1.2 ± 0.3 0.39 1.3 ± 0.3 1.2 ± 0.4 0.9 0.6 -0.21 0.36
COX-2 T 1.04 ± 0.2 1.0 ± 0.3 0.19 1.1 ± 0.3 1.04 ± 0.3 0.9 0.3 -0.13 0.39
Plasma
Plasma PGE2 521 ± 306 690 ± 556 0.28 650 ± 701 615 ± 825 0.6 0.2 -129 503
Results are presented as mean ± standard deviation
a P value between baseline and intervention
b Treatment effect: difference between end value and start value
c After exclusion of the patients that received the treatment for less than 8 months (n = 4, 50% placebo), no treatment effect was found
G glucuronidase (GUS) chosen as housekeeping gene
T tata binding protein (TBP) chosen as housekeeping gene
COX cyclooxygenase
Table 4 Pearson coefﬁcients (r) of correlation between dietary intake of omega-3 and omega-6 fatty acids and the treatment effect (inter-
vention–baseline): changes in fatty acid composition in duodenal lesions (weight %) from patients with familial adenomatous polyposis (n = 38)
Differences (stop–baseline) in duodenal lesions Dietary intake (% of total fat)
Sum omega-3 fatty acids EPA ? DHA Sum omega-6 fatty acids
Myristic acid -0.48 -0.01 -0.58*
Stearic acid 0.72** 0.22 0.56*
ALA -0.48 0.20 -0.82**
EPA 0.02 -0.52 0.76**
DHA -0.03 -0.52 0.70**
Omega-3 fatty acids -0.35 -0.59* 0.44
Ratio ALA/LA -0.42 0.17 -0.75**
Ratio AA/LA 0.44 -0.11 0.58*
Only signiﬁcant results are shown
** Correlation is signiﬁcant at the 0.01 level (2-tailed)
* Correlation is signiﬁcant at the 0.05 level (2-tailed)
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123concentrations in cancer cells. The levels of neither COX-2
in lesions, nor plasma PGE2, were reduced after treatment.
The levels of COX-2 in duodenal lesions and plasma PGE2
also did not vary between FAP patients and healthy sub-
jects. A signiﬁcant change in the Rofecoxib treated group,
separately, in duodenal biopsy expression levels of COX-1
was found, but only when TBP was used as the house-
keeping gene. Notably, the outcome for the comparisons
between FAP patients and healthy subjects regarding both
COX-1 and COX-2 expression in leucocytes was also
dependent on the choice of housekeeping gene. We will not
speculate on the importance of these ﬁndings.
The intake of omega-3 fatty acids was lower than the
minimum recommendation of 0.5% of energy in the
patients not taking omega-3 supplements [41, 42]. Notably,
cancer patients are generally advised to take supplements
with very long chain omega-3 fatty acids, and to follow the
general dietary guidelines [43]. FAP patients are at high
cancer risk, and the present study suggests that dietary
modiﬁcation should follow chemoprevention in FAP
patients. Fatty acids are nearly 100% absorbed, and pre-
vious studies have shown that the correlation between FA
in diet and serum phospholipids lipids is high. Correlations
between individual FAs in diet and duodenal biopsies have,
to our knowledge, not been reported previously. Thus, the
results are biologically meaningful since simple dietary
advice might change the EFA status even in a FAP patient.
We would suggest that the nutrient intake among FAP
patients should at least meet the recommendations for
healthy subjects, and in particular with regard to essential
fatty acids. Clinicians should thus involve clinical nutri-
tionists in the treatment of such patients.
The design, a prospective double-blind randomized
placebo-controlled trial is a key strength to this study. A
good sample of FAP patients was recruited for the study,
and the number enrolled is close to the maximum possible
in terms of eligible Norwegian patients. Certainly sample
size imposes obvious restrictions on conclusions. We could
have applied the Bonferroni correction to address the
problem of multiple comparisons by adjusting the P-values.
However, the comparable effects were observed both in
blood samples and duodenal biopsies. Exclusion of the
patients who received treatment for less than 8 months from
the statistical analysis, however, did not change the out-
come of the study. We do not think that poor compliance
may explain any lack of effect, since in both groups, com-
pliance was close to 90%. Findings were similar in duo-
denal lesions and serum phospholipids, which supports the
relevance of investigating fatty acid metabolism in FAP. To
the best of our knowledge no previous study has investi-
gated the fatty acid composition of duodenal lesions from
FAP patients. This drug might have a direct inﬂuence on the
fatty acid metabolism pathways in the gut epithelium. One
possible explanation for the lack of modulation of COX2
levels is possibly that the drug was simply not getting to the
epithelium. In this regard, direct measures of rofecoxib in
both the blood and in the duodenum, by the chromato-
graphic methods otherwise employed, should be imple-
mented in future comparable studies. The delay in
processing and publishing the clinical data is unfortunate,
but with the drug withdrawn, the urgency to publish was
somewhat precluded. Initially after the withdrawal of the
drug, our focus was on assuring the cardiovascular status of
our participants and various aspects of follow-up. More-
over, we still believe that the conclusions drawn are valid,
and in contrast to other papers, this interdisciplinary paper
suggests the relevance of clinical nutrition for better treat-
ment of such patients. Future FAP studies should study fatty
acid status and metabolism, molecular mechanisms relevant
to essential fatty acid metabolism, inﬂammation and angi-
ogenesis, as well as nutrition requirements.
In conclusion, the study indicated that several signiﬁcant
Rofecoxib-related, non-beneﬁcial changes were found in
the fatty acid distribution of both serum phospholipids and
duodenal lesions. In contrast, no treatment effects on the
mRNA expression of COX-1 and COX-2 in the same tis-
sues, nor in the levels of plasma PGE2, were found. Dietary
intake of fatty acids was reﬂected in the composition of
fatty acids in both serum phospholipids and duodenal
lesions. Furthermore, both dietary and supplemental intake
of omega-3 fatty acids was found to be beneﬁcially related
to EFA status.
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